The risk of serious skin toxicities involving rash or dermatitis was substantially higher with EGFR inhibitor-based chemotherapy (Figure 8): cetuximab-based chemotherapy (RR 13.64; 95% CI 7.04–26.43) or panitumumab-based chemotherapy (RR 22.42; 95% CI 10.18–49.34). Here, EGFR is linked to dermatitis.